Following the European Commission's inquiry into the pharmaceutical industry, a consultation process was launched. In response to the consultation process, the European Commission has received over forty submissions which will be posted on the competition website.

The inquiry was initiated as part of a report by the Commission last year in response to allegations that pharmaceutical companies in Europe were attempting to delay the entry of generic medicines onto the market as well as blocking competitors' efforts to develop new drugs.

The Commission, as part of its investigation, initiated a public consultation process in an effort to encourage debate of the investigation's preliminary results. The results of this process are intended to be published later this year.

Jonathan Todd, the EU executive's internal market spokesperson, confirmed that, as per common practice at the Commission, the comments received as part of the consultation process will be considered when the Commission draws up its definitive report on the pharmaceutical sector inquiry.

For more information, please see:  

http://www.euractiv.com/en/health/commission-publish-submissions-pharma-inquiry/article-179070